FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
NIH Panel Calls for Further Research On End-of-Life Issues.
NAS Committee Urges Greater Rewards For Interdisciplinary Research.
CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
Funding Opportunities Listed.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40% - California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Facing stage 4 cholangiocarcinoma, Keaton Herzer moved mountains to take off-label therapy, get a transplant
Two years later, he has no evidence of disease - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
